EP3440112A4 - Methods for treating cancer - Google Patents
Methods for treating cancer Download PDFInfo
- Publication number
- EP3440112A4 EP3440112A4 EP17779975.6A EP17779975A EP3440112A4 EP 3440112 A4 EP3440112 A4 EP 3440112A4 EP 17779975 A EP17779975 A EP 17779975A EP 3440112 A4 EP3440112 A4 EP 3440112A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- treating cancer
- cancer
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662319857P | 2016-04-08 | 2016-04-08 | |
PCT/US2017/026819 WO2017177230A1 (en) | 2016-04-08 | 2017-04-10 | Methods for treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3440112A1 EP3440112A1 (en) | 2019-02-13 |
EP3440112A4 true EP3440112A4 (en) | 2019-10-09 |
Family
ID=60001518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17779975.6A Pending EP3440112A4 (en) | 2016-04-08 | 2017-04-10 | Methods for treating cancer |
Country Status (6)
Country | Link |
---|---|
US (1) | US11337969B2 (en) |
EP (1) | EP3440112A4 (en) |
JP (2) | JP2019510785A (en) |
CN (1) | CN109153722A (en) |
CA (1) | CA3019394A1 (en) |
WO (1) | WO2017177230A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109069426B (en) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | Methods of treating cancer |
WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
JP7054529B2 (en) | 2016-06-21 | 2022-04-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | CXCR4 inhibitor and its use |
EP3707158A4 (en) * | 2017-11-07 | 2021-12-01 | X4 Pharmaceuticals, Inc. | Cancer biomarkers and methods of use thereof |
CA3095331A1 (en) * | 2018-04-13 | 2019-10-17 | X4 Pharmaceuticals, Inc. | Cancer serum biomarkers and methods of use thereof |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
CN116741409A (en) * | 2023-05-12 | 2023-09-12 | 中国医学科学院北京协和医院 | Application of model constructed based on peripheral blood biomarker in predicting upper gastrointestinal tumor chemotherapy efficacy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015019284A2 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
US4933447A (en) | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
US5021409A (en) | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
US6001826A (en) | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
GB9126677D0 (en) | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
GB9200245D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
US5235056A (en) | 1992-04-22 | 1993-08-10 | Ciba-Geigy Corporation | Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith |
GB9400411D0 (en) | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
US6506770B1 (en) | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
GB9511357D0 (en) | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
WO1997009976A2 (en) | 1995-09-01 | 1997-03-20 | Washington University | Method of reducing neurotoxic injury with zinc chelators |
AU719633B2 (en) | 1996-03-22 | 2000-05-11 | Du Pont Pharmaceuticals Company | Novel asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs |
CN1231215C (en) | 1997-06-02 | 2005-12-14 | 詹森药业有限公司 | (Imidazol-5-yl) methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
AU8576098A (en) | 1997-07-25 | 1999-02-16 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
ES2255733T3 (en) | 1997-09-30 | 2006-07-01 | Daiichi Pharmaceutical Co., Ltd. | SULFONYL DERIVATIVES. |
GB9726229D0 (en) | 1997-12-12 | 1998-02-11 | Zeneca Ltd | Resolution of chiral amines |
BR9813691A (en) | 1997-12-19 | 2000-10-10 | Takeda Chemical Industries Ltd | Pharmaceutical composition to antagonize ccr5, use of the compound or a salt thereof in combination with a protease inhibitor and / or a reverse transcriptase inhibitor, and process for antagonizing ccr5. |
US6607799B1 (en) | 1998-10-15 | 2003-08-19 | 3M Innovative Properties Company | Surgical dressing with delivery system and method of manufacture |
US6635278B1 (en) | 1998-12-15 | 2003-10-21 | Gilead Sciences, Inc. | Pharmaceutical formulations |
US6365583B1 (en) | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
HUP0200761A3 (en) | 1999-03-24 | 2003-05-28 | Anormed Inc Langley | Chemokine receptor binding heterocyclic compounds, pharmaceutical compositions containing them and their use |
US6245799B1 (en) | 1999-11-08 | 2001-06-12 | American Home Products Corp | [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders |
US6602872B1 (en) | 1999-12-13 | 2003-08-05 | Merck & Co., Inc. | Substituted pyridazines having cytokine inhibitory activity |
US6683192B2 (en) | 2000-03-30 | 2004-01-27 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
ATE335733T1 (en) | 2000-09-15 | 2006-09-15 | Anormed Inc | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS |
IL154227A0 (en) | 2000-09-15 | 2003-07-31 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
US6835731B2 (en) | 2000-09-15 | 2004-12-28 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
EA007538B1 (en) | 2000-12-11 | 2006-10-27 | Туларик Инк. | Cxcr3 antagonists |
US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
GB0107228D0 (en) | 2001-03-22 | 2001-05-16 | Astrazeneca Ab | Chemical compounds |
DE60217322T2 (en) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclic compound and antitumor agent containing it as an active ingredient |
US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
AU2002318927B2 (en) | 2001-07-31 | 2007-01-04 | Genzyme Corporation | Methods to mobilize progenitor/stem cells |
US7169750B2 (en) | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
CN101353324A (en) | 2001-09-12 | 2009-01-28 | 阿诺麦德股份有限公司 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings |
KR20040068339A (en) | 2001-12-21 | 2004-07-30 | 아노르메드 인코포레이티드 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
US7491544B2 (en) | 2002-05-20 | 2009-02-17 | New York University | Chiral piperidine and quinucledine ligands |
WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
US7759336B2 (en) | 2002-12-10 | 2010-07-20 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
SG160211A1 (en) | 2003-04-03 | 2010-04-29 | Semafore Pharmaceuticals Inc | Pi-3 kinase inhibitor prodrugs |
US7291631B2 (en) | 2003-04-11 | 2007-11-06 | Genzyme Corporation | CXCR4 chemokine receptor binding compounds |
US7501518B2 (en) | 2003-04-22 | 2009-03-10 | Genzyme Corporation | Methods of making 2,6-diaryl piperidine derivatives |
WO2004093817A2 (en) | 2003-04-22 | 2004-11-04 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
CA2527583C (en) | 2003-05-30 | 2013-12-17 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
AU2004257167B2 (en) | 2003-07-03 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
CN1930127B (en) | 2004-03-15 | 2012-11-21 | 阿诺麦德股份有限公司 | Process for the synthesis of cxcr4 antagonist |
CA2561718A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
DE102004021716A1 (en) | 2004-04-30 | 2005-12-01 | Grünenthal GmbH | Substituted imidazo [1,2-a] pyridine compounds and drugs containing substituted imidazo [1,2-a] pyridine compounds |
CN101031569B (en) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
TW200612935A (en) | 2004-08-02 | 2006-05-01 | Smithkline Beecham Corp | Chemical compounds |
AU2005277638A1 (en) | 2004-08-16 | 2006-03-02 | Smithkline Beecham Corporation | Chemical compounds |
WO2006026703A2 (en) | 2004-09-02 | 2006-03-09 | Smithkline Beecham Corporation | Chemical compounds |
EP1793825A4 (en) | 2004-09-24 | 2009-12-09 | Smithkline Beecham Corp | Chemcial compounds |
TW200619206A (en) | 2004-09-29 | 2006-06-16 | Anormed Inc | Chemokine-binding heterocyclic compound salts, and methods of use thereof |
EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
EP1853604A4 (en) | 2005-03-04 | 2010-02-24 | Smithkline Beecham Corp | Chemical compounds |
KR101509440B1 (en) | 2005-05-12 | 2015-04-07 | 애브비 바하마스 리미티드 | Apoptosis promoters |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
DE602006015966D1 (en) | 2005-07-08 | 2010-09-16 | Siemens Healthcare Diagnostics | METHOD FOR PREDICTING AND MONITORING AN IMMEDIATE RESPONSE TO CANCER THERAPY |
EP1904501A2 (en) | 2005-07-11 | 2008-04-02 | Smithkline Beecham Corporation | Chemical compounds |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
EP1910426B1 (en) | 2005-08-02 | 2018-01-03 | Ineos Sales (UK) Limited | Diene polymerisation |
AU2006280945A1 (en) | 2005-08-19 | 2007-02-22 | Genzyme Corporation | Methods to enhance chemotherapy |
JP2009507795A (en) | 2005-08-31 | 2009-02-26 | スミスクライン ビーチャム コーポレーション | Compound |
CN103819416A (en) | 2005-10-07 | 2014-05-28 | 埃克塞里艾克西斯公司 | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
PL1961744T3 (en) | 2005-11-18 | 2013-09-30 | Ono Pharmaceutical Co | Basic group-containing compound and use thereof |
CA2629037A1 (en) | 2005-11-30 | 2007-06-07 | Schering Corporation | Compositions comprising a combination of ccr5 and cxcr4 antagonists |
HUE030235T2 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
JP2009524689A (en) | 2006-01-25 | 2009-07-02 | スミスクライン ビーチャム コーポレーション | Compound |
EP1984376A4 (en) | 2006-01-25 | 2009-04-08 | Smithkline Beecham Corp | Chemical compounds |
GB0605786D0 (en) | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
CN101472930B (en) | 2006-04-26 | 2011-12-14 | 霍夫曼-拉罗奇有限公司 | Thieno [3, 2-d] pyrimidine derivative useful as pi3K inhibitor |
EP2043640A2 (en) | 2006-06-12 | 2009-04-08 | Pfizer Products Inc. | Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients |
TWI482772B (en) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | Compositions, suitable for oral administration, comprising a triazolo(4,5-d)pyrimidin derivate |
EP2526933B1 (en) | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
ES2557930T3 (en) | 2007-03-12 | 2016-01-29 | Ym Biosciences Australia Pty Ltd | Phenylaminopyrimidine compounds and uses thereof |
WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
EP2155747B1 (en) | 2007-05-10 | 2012-10-24 | GE Healthcare Limited | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
WO2009026251A1 (en) | 2007-08-17 | 2009-02-26 | The General Hospital Corporation | Detecting ions and measuring ion concentrations |
US9101628B2 (en) | 2007-09-18 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and composition of treating a flaviviridae family viral infection |
ES2602577T3 (en) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
MX2010010198A (en) | 2008-03-20 | 2010-12-21 | Carolus Therapeutics Inc | Methods of treating inflammation. |
BRPI0909375A2 (en) | 2008-03-28 | 2015-08-04 | Altiris Therapeutics | Chemokine Receptor Modulators |
WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
JP2010016628A (en) | 2008-07-03 | 2010-01-21 | Canon Inc | Image processing device and image processing method |
EP2328618B1 (en) | 2008-08-13 | 2017-11-29 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4- oxoquinoline-3-carboxamide and administration thereof |
KR101687841B1 (en) | 2008-12-09 | 2016-12-19 | 길리애드 사이언시즈, 인코포레이티드 | Modulators of toll-like receptors |
EP2213288A1 (en) | 2009-01-30 | 2010-08-04 | Karl Welte | NAMPT and vitamin B3 for treating or preventing diseases |
EP2482805B1 (en) | 2009-09-28 | 2014-11-19 | Zenbury International Limited | Pharmaceutical composition |
CA2706292A1 (en) | 2010-05-28 | 2011-11-28 | Pharmascience Inc. | A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide |
US20110293686A1 (en) | 2010-05-28 | 2011-12-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-viral compositions and methods for administration |
WO2012047339A2 (en) | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
US9267934B2 (en) | 2010-10-26 | 2016-02-23 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
ES2607604T3 (en) | 2010-12-03 | 2017-04-03 | Emory University | Chemokine CXCR4 receptor modulators and related uses |
WO2012078633A2 (en) | 2010-12-07 | 2012-06-14 | Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene | Methods of inhibiting metastasis from cancer |
BR122021026169B1 (en) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | USE OF A CELL |
CN103476410B (en) | 2011-01-11 | 2020-02-21 | 戴麦里克斯生物科学有限公司 | Combination therapy |
JP2014513727A (en) | 2011-05-16 | 2014-06-05 | ジェンザイム・コーポレーション | Use of CXCR4 antagonist |
AR087363A1 (en) | 2011-07-29 | 2014-03-19 | Pf Medicament | USE OF ANTIBODY I-3859 FOR THE DETECTION AND DIAGNOSIS OF CANCERES |
AR087364A1 (en) | 2011-07-29 | 2014-03-19 | Pf Medicament | ANTI-CXCR4 ANTIBODY AND ITS USE FOR CANCERES DETECTION AND DIANOSTIC |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
WO2013106732A1 (en) | 2012-01-12 | 2013-07-18 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
AU2013347838A1 (en) | 2012-11-26 | 2015-06-11 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
US10064826B2 (en) | 2013-03-15 | 2018-09-04 | Navinta, Llc | Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process |
CN105451818A (en) | 2013-06-05 | 2016-03-30 | 萨克生物研究学院 | Vitamin D receptor agonists to treat diseases involving CXCL12 activity |
AT512724B1 (en) | 2013-07-12 | 2015-02-15 | Avl List Gmbh | Device and method for the continuous measurement of the dynamic fuel consumption of an internal combustion engine |
TWI623551B (en) * | 2013-08-02 | 2018-05-11 | 輝瑞大藥廠 | Anti-cxcr4 antibodies and antibody-drug conjugates |
MX2016002185A (en) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds. |
CA2922398C (en) | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
BR112016010224A2 (en) | 2013-11-05 | 2018-05-02 | Cognate Bioservices, Inc. | checkpoint inhibitor combinations and therapeutic products to treat cancer. |
US20170088626A1 (en) | 2014-03-05 | 2017-03-30 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
WO2015143092A1 (en) | 2014-03-18 | 2015-09-24 | The Research Foundation For The State University Of New York | Therapeutic agent for treating tumors |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
US9394305B2 (en) | 2014-06-23 | 2016-07-19 | Dr. Reddy's Laboratories Ltd. | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors |
US10555981B2 (en) | 2014-07-16 | 2020-02-11 | Transgene S.A. | Oncolytic virus for expression of immune checkpoint modulators |
WO2016089872A1 (en) | 2014-12-03 | 2016-06-09 | Glycomimetics, Inc. | Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors |
JP2018505658A (en) | 2014-12-09 | 2018-03-01 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Systems and methods for obtaining genetic signature biomarkers of response to PD-1 antagonists |
KR20170105514A (en) | 2014-12-12 | 2017-09-19 | 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 | Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist |
US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
CA2989144A1 (en) | 2015-06-12 | 2016-12-15 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
NZ740616A (en) | 2015-09-14 | 2023-05-26 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same |
US10379661B2 (en) | 2015-09-25 | 2019-08-13 | Samsung Electronics Co., Ltd. | Coordinate measuring apparatus and coordinate measuring system having the same |
CN109069426B (en) | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | Methods of treating cancer |
WO2017106332A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
US10610527B2 (en) | 2015-12-22 | 2020-04-07 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
CN108883132A (en) | 2016-01-22 | 2018-11-23 | X4 制药有限公司 | Method for treating cancer |
KR102436984B1 (en) | 2016-04-14 | 2022-08-26 | 크리에티브이 마이크로테크, 인크. | Methods of Using PD-L1 Expression in Treatment Decisions for Cancer Therapy |
JP2019518006A (en) | 2016-04-29 | 2019-06-27 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | HCK as a Therapeutic Target in MYD 88 Mutant Disease |
CA3027495A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
CA3027500A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
JP7054529B2 (en) | 2016-06-21 | 2022-04-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | CXCR4 inhibitor and its use |
CA3066778A1 (en) | 2017-06-21 | 2018-12-27 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
EP3707158A4 (en) | 2017-11-07 | 2021-12-01 | X4 Pharmaceuticals, Inc. | Cancer biomarkers and methods of use thereof |
JP2021506838A (en) | 2017-12-19 | 2021-02-22 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Acyclic CXCR4 Inhibitors and Their Use |
CA3095331A1 (en) | 2018-04-13 | 2019-10-17 | X4 Pharmaceuticals, Inc. | Cancer serum biomarkers and methods of use thereof |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
US20230346772A1 (en) | 2019-12-18 | 2023-11-02 | X4 Pharmaceuticals, Inc. | Combination treatments for waldenstrom's macroglobulinemia |
EP4117662A4 (en) | 2020-03-10 | 2024-04-03 | X4 Pharmaceuticals Inc | Methods for treating neutropenia |
-
2017
- 2017-04-10 JP JP2018552218A patent/JP2019510785A/en not_active Ceased
- 2017-04-10 EP EP17779975.6A patent/EP3440112A4/en active Pending
- 2017-04-10 WO PCT/US2017/026819 patent/WO2017177230A1/en active Application Filing
- 2017-04-10 CA CA3019394A patent/CA3019394A1/en active Pending
- 2017-04-10 US US16/091,689 patent/US11337969B2/en active Active
- 2017-04-10 CN CN201780026962.6A patent/CN109153722A/en active Pending
-
2022
- 2022-01-27 JP JP2022010811A patent/JP2022044767A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015019284A2 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
Non-Patent Citations (1)
Title |
---|
US NATIONAL LIBRARY MEDICINE: "Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors (CXCessoR4)", 16 June 2015 (2015-06-16), XP002793692, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT02472977> [retrieved on 20190820] * |
Also Published As
Publication number | Publication date |
---|---|
US20190160051A1 (en) | 2019-05-30 |
JP2019510785A (en) | 2019-04-18 |
EP3440112A1 (en) | 2019-02-13 |
US11337969B2 (en) | 2022-05-24 |
JP2022044767A (en) | 2022-03-17 |
WO2017177230A1 (en) | 2017-10-12 |
CN109153722A (en) | 2019-01-04 |
CA3019394A1 (en) | 2017-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3641770A4 (en) | Methods for treating cancer | |
EP3488001A4 (en) | Treating cancer | |
HK1251407A1 (en) | Methods for treating cancer | |
EP3423488A4 (en) | Methods of treating cancer | |
EP3500289A4 (en) | Methods for treating tracheobronchomalacia | |
EP3393475A4 (en) | Methods of treating cancer | |
EP3180010A4 (en) | Combination therapy for treating cancer | |
EP3110509A4 (en) | Method for treating cancer | |
EP3407978A4 (en) | Combination therapy for treating cancer | |
EP3220916A4 (en) | Method for treating cancer | |
EP3405203A4 (en) | Methods for treating cancer | |
EP3285773A4 (en) | Combination therapy for treating cancer | |
EP3206688A4 (en) | Method for treating cancer | |
EP3606962A4 (en) | Methods for treating cd73hi tumors | |
EP3268087A4 (en) | METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS | |
EP3389634A4 (en) | Methods for treating cancer | |
EP3440112A4 (en) | Methods for treating cancer | |
EP3341080A4 (en) | Method for treating cancer | |
EP3177292A4 (en) | Compounds and methods for treating cancer | |
EP3193884A4 (en) | Combination therapy for treating cancer | |
EP3359255A4 (en) | Combination therapies for treating cancer | |
EP3389652A4 (en) | Methods for treating cancer | |
EP3442946A4 (en) | Methods of treating cancer | |
HK1250944A1 (en) | Methods for treating cancer | |
EP3589659A4 (en) | Compounds and methods for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180928 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20190828BHEP Ipc: A61K 39/00 20060101ALI20190828BHEP Ipc: C07K 16/28 20060101AFI20190828BHEP Ipc: A61K 39/395 20060101ALI20190828BHEP Ipc: A61K 45/06 20060101ALI20190828BHEP Ipc: A61K 38/17 20060101ALI20190828BHEP Ipc: A61K 31/4709 20060101ALI20190828BHEP Ipc: A61K 9/48 20060101ALI20190828BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20190906 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40001826 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20210330 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |